141 related articles for article (PubMed ID: 21696866)
21. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
Sawyer JS; Anderson BD; Beight DW; Campbell RM; Jones ML; Herron DK; Lampe JW; McCowan JR; McMillen WT; Mort N; Parsons S; Smith EC; Vieth M; Weir LC; Yan L; Zhang F; Yingling JM
J Med Chem; 2003 Sep; 46(19):3953-6. PubMed ID: 12954047
[TBL] [Abstract][Full Text] [Related]
22. Discovery of a series of 2-(1H-pyrazol-1-yl)pyridines as ALK5 inhibitors with potential utility in the prevention of dermal scarring.
Boys ML; Bian F; Kramer JB; Chio CL; Ren XD; Chen H; Barrett SD; Sexton KE; Iula DM; Filzen GF; Nguyen MN; Angell P; Downs VL; Wang Z; Raheja N; Ellsworth EL; Fakhoury S; Bratton LD; Keller PR; Gowan R; Drummond EM; Maiti SN; Hena MA; Lu L; McConnell P; Knafels JD; Thanabal V; Sun F; Alessi D; McCarthy A; Zhang E; Finzel BC; Patel S; Ciotti SM; Eisma R; Payne NA; Gilbertsen RB; Kostlan CR; Pocalyko DJ; Lala DS
Bioorg Med Chem Lett; 2012 May; 22(10):3392-7. PubMed ID: 22542194
[TBL] [Abstract][Full Text] [Related]
23. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
Gellibert F; de Gouville AC; Woolven J; Mathews N; Nguyen VL; Bertho-Ruault C; Patikis A; Grygielko ET; Laping NJ; Huet S
J Med Chem; 2006 Apr; 49(7):2210-21. PubMed ID: 16570917
[TBL] [Abstract][Full Text] [Related]
24. Application of Pd-Catalyzed Cross-Coupling Reactions in the Synthesis of 5,5-Dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles that Inhibit ALK5 Kinase.
Tenora L; Galeta J; Řezníčková E; Kryštof V; Potáček M
J Org Chem; 2016 Dec; 81(23):11841-11856. PubMed ID: 27934472
[TBL] [Abstract][Full Text] [Related]
25. Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.
Li HY; Wang Y; Heap CR; King CH; Mundla SR; Voss M; Clawson DK; Yan L; Campbell RM; Anderson BD; Wagner JR; Britt K; Lu KX; McMillen WT; Yingling JM
J Med Chem; 2006 Mar; 49(6):2138-42. PubMed ID: 16539403
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and antifibrosis evaluation of 4-(benzo-[c][1,2,5]thiadiazol-5-yl)-3(5)-(6-methyl- pyridin-2-yl)pyrazole and 3(5)-(6-methylpyridin- 2-yl)-4-(thieno-[3,2,-c]pyridin-2-yl)pyrazole derivatives.
Zhu WJ; Cui BW; Wang HM; Nan JX; Piao HR; Lian LH; Jin CH
Eur J Med Chem; 2019 Oct; 180():15-27. PubMed ID: 31299584
[TBL] [Abstract][Full Text] [Related]
27. Design and synthesis of 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles and pyrazolo[3,4-b]pyridines for Aurora-A kinase inhibitors.
Shi J; Xu G; Zhu W; Ye H; Yang S; Luo Y; Han J; Yang J; Li R; Wei Y; Chen L
Bioorg Med Chem Lett; 2010 Jul; 20(14):4273-8. PubMed ID: 20621733
[TBL] [Abstract][Full Text] [Related]
28. 5-(1,3-Benzothiazol-6-yl)-4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazole derivatives as potent and selective transforming growth factor-β type I receptor inhibitors.
Amada H; Sekiguchi Y; Ono N; Koami T; Takayama T; Yabuuchi T; Katakai H; Ikeda A; Aoki M; Naruse T; Wada R; Nozoe A; Sato M
Bioorg Med Chem; 2012 Dec; 20(24):7128-38. PubMed ID: 23117174
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors.
Sabat M; Wang H; Scorah N; Lawson JD; Atienza J; Kamran R; Hixon MS; Dougan DR
Bioorg Med Chem Lett; 2017 May; 27(9):1955-1961. PubMed ID: 28359790
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and evaluation of small molecule imidazo[2,1-b][1,3,4]thiadiazoles as inhibitors of transforming growth factor-β type-I receptor kinase (ALK5).
Patel HM; Sing B; Bhardwaj V; Palkar M; Shaikh MS; Rane R; Alwan WS; Gadad AK; Noolvi MN; Karpoormath R
Eur J Med Chem; 2015 Mar; 93():599-613. PubMed ID: 25234355
[TBL] [Abstract][Full Text] [Related]
31. Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines.
Li HY; Wang Y; Yan L; Campbell RM; Anderson BD; Wagner JR; Yingling JM
Bioorg Med Chem Lett; 2004 Jul; 14(13):3585-8. PubMed ID: 15177480
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and biological evaluation of pyrazole derivatives as potential multi-kinase inhibitors in hepatocellular carcinoma.
Strocchi E; Fornari F; Minguzzi M; Gramantieri L; Milazzo M; Rebuttini V; Breviglieri S; Camaggi CM; Locatelli E; Bolondi L; Comes-Franchini M
Eur J Med Chem; 2012 Feb; 48():391-401. PubMed ID: 22227043
[TBL] [Abstract][Full Text] [Related]
33. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological evaluation of novel 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor beta 1 type 1 receptor.
Kim DK; Kim J; Park HJ
Bioorg Med Chem Lett; 2004 May; 14(10):2401-5. PubMed ID: 15109621
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.
Lv PC; Li DD; Li QS; Lu X; Xiao ZP; Zhu HL
Bioorg Med Chem Lett; 2011 Sep; 21(18):5374-7. PubMed ID: 21802290
[TBL] [Abstract][Full Text] [Related]
36. Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5).
Goldberg FW; Ward RA; Powell SJ; Debreczeni JE; Norman RA; Roberts NJ; Dishington AP; Gingell HJ; Wickson KF; Roberts AL
J Med Chem; 2009 Dec; 52(23):7901-5. PubMed ID: 19736928
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
Sawyer JS; Beight DW; Britt KS; Anderson BD; Campbell RM; Goodson T; Herron DK; Li HY; McMillen WT; Mort N; Parsons S; Smith EC; Wagner JR; Yan L; Zhang F; Yingling JM
Bioorg Med Chem Lett; 2004 Jul; 14(13):3581-4. PubMed ID: 15177479
[TBL] [Abstract][Full Text] [Related]
38. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors.
Gellibert F; Woolven J; Fouchet MH; Mathews N; Goodland H; Lovegrove V; Laroze A; Nguyen VL; Sautet S; Wang R; Janson C; Smith W; Krysa G; Boullay V; De Gouville AC; Huet S; Hartley D
J Med Chem; 2004 Aug; 47(18):4494-506. PubMed ID: 15317461
[TBL] [Abstract][Full Text] [Related]
39. Screening and identification of a novel class of TGF-β type 1 receptor kinase inhibitor.
Huynh QK; Wise SJ; Koch KA; Castonguay LA; Reid BG; Pagratis EE; Koditek D; Glascock CB; Pitts KR; Turner BA; Liu X; Hung M; Han B; Pagratis N
J Biomol Screen; 2011 Aug; 16(7):724-33. PubMed ID: 21521800
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of 5-substituted 1,4-dihydroindeno[1,2-c]pyrazoles as multitargeted receptor tyrosine kinase inhibitors.
Akritopoulou-Zanze I; Albert DH; Bousquet PF; Cunha GA; Harris CM; Moskey M; Dinges J; Stewart KD; Sowin TJ
Bioorg Med Chem Lett; 2007 Jun; 17(11):3136-40. PubMed ID: 17391959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
